HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 58.23% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Chardan Capital reduced their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Leerink Partners initiated coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Piper Sandler reissued an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Zura Bio has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Price Performance

Zura Bio stock opened at $3.16 on Monday. The company’s fifty day moving average price is $4.20 and its two-hundred day moving average price is $4.11. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Sell-side analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Insider Activity

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently made changes to their positions in the stock. Great Point Partners LLC increased its holdings in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after buying an additional 1,884,501 shares during the last quarter. Armistice Capital LLC grew its position in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares during the period. Braidwell LP acquired a new position in shares of Zura Bio during the 3rd quarter worth about $10,040,000. Point72 Asset Management L.P. bought a new stake in shares of Zura Bio in the 2nd quarter valued at about $8,446,000. Finally, Geode Capital Management LLC lifted its stake in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after purchasing an additional 377,545 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.